A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of distinct molecular alterations with corresponding targeted therapies is modifying this thera...
Guardado en:
Autores principales: | Giacomo Aimar, Chiara Paratore, Clizia Zichi, Donatella Marino, Elisa Sperti, Andrea Caglio, Teresa Gamba, Francesca De Vita, Massimo Di Maio |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Open Exploration Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/46affa1a81044e6ca6b2213bb2362c97 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin
por: AVILA,ANA D, et al.
Publicado: (2007) -
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021) -
Mutaciones del gen del receptor 3 del Factor de Crecimiento de Fibroblasto (FGFR3) en pacientes chilenos con talla baja idiopática, hipocondroplasia y acondroplasia
por: Mancilla V,Edna E, et al.
Publicado: (2003) -
ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
por: Ghazala Sadaf, et al.
Publicado: (2020) -
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)